The text presents unaudited financial statements for Boston Scientific Corporation and its subsidiaries for the periods ended June 30, 2021 and 2020, detailing metrics such as net sales, operating expenses, net income, and various financial figures including assets, liabilities, and equity. It also provides information on derivative and nonderivative assets and liabilities, fair value measurements categorized under different valuation hierarchy levels, debt obligations like notes and commitments, and the company's compliance with financial covenant requirements for credit arrangements. These elements collectively offer a comprehensive overview of the company's financial performance and obligations as of June 30, 2021.
Boston Scientific Corporation is a global medical device company specializing in interventional medical specialties aiming to improve patient health. The company has seen substantial growth in net sales, partly due to strategic acquisitions. The COVID-19 pandemic impacted operations and financial performance, leading to a decline in sales, but with some recovery seen in the second quarter of 2021. Financially, net sales increased by 53.6% in the second quarter of 2021 compared to the same period in 2020, with reported net income improvements. For the first six months of 2021, net sales were up by 28.2%, with a reported net income increase as well. Cash provided by operating activities for the first six months of 2021 was $927 million, while the company had total outstanding debt of $9.109 billion as of June 30, 2021. Boston Scientific Corporation also announced a global restructuring program, voluntary product recall, and notable financial activities such as the acquisition of Farapulse and losses on investments. Tax rates fluctuated due to various receipts and charges, with economic relief legislation impacting operations. The company managed liquidity and capital resources proactively during the pandemic. Financing activities showed a net cash outflow.
The company operates globally and faces market risks related to currency exchange rates and interest rates. They use derivatives for risk management, following corporate policies and avoiding speculative transactions. Currency risks come from commitments, transactions, and investments in foreign currencies, managed through both nonderivative and derivative instruments. The company had $10.343 billion in currency derivatives as of June 30, 2021. Interest rate risk is managed by offsetting U.S. dollar borrowings with cash investments and previously using derivative instruments. As of June 30, 2021, all outstanding debt had fixed interest rates. More details on derivative instruments can be found in the company's financial statements.
The text provides an update on the evaluation of disclosure controls and procedures, conducted by management, including the Chief Executive Officer (CEO) and Chief Financial Officer (CFO), as of June 30, 2021, confirming that these controls were effective. Additionally, it states that there were no significant changes in internal control over financial reporting in the second quarter of 2021, despite employees working remotely due to COVID-19. The company continued to maintain financial reporting systems and controls effectively through the use of electronic tools and remote work processes.
Refer to Note G - Income Taxes and Note H - Commitments and Contingencies in the unaudited consolidated financial statements in Item 1 of the Quarterly Report on Form 10-Q for information on legal proceedings.
Consider the risk factors discussed in Part I, Item 1A of our latest Annual Report on Form 10-K, as they could significantly impact our business, financial condition, or future outcomes.
I'm sorry, but it seems like there are no parts of text provided for me to summarize. Could you resend the text you would like me to summarize?
I'm sorry, but I cannot provide a summary without the text that needs to be summarized. Please provide the text so I can create a summary for you.
I'm ready to help. Please provide the text that you would like me to summarize.
I'm sorry, but I will need you to provide me with the text in parts as instructed in order to summarize it for you. Please proceed with sending the text in parts.
The text provided consists of financial documentation related to Boston Scientific Corporation, including a Credit Agreement dated May 10, 2021, certifications of the Chief Executive Officer and Chief Financial Officer according to the Sarbanes-Oxley Act of 2002, and various XBRL documents. The document is signed by Daniel J. Brennan, Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, in accordance with the Securities Exchange Act of 1934 requirements.
